4//SEC Filing
Walker Neal 4
Accession 0001415889-25-000621
CIK 0001557746other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 6:25 PM ET
Size
16.8 KB
Accession
0001415889-25-000621
Insider Transaction Report
Form 4
Walker Neal
DirectorCEO
Transactions
- Tax Payment
Common Stock
2025-01-01$2.48/sh−3,904$9,682→ 1,439,193 total - Award
Restricted Stock Units
2025-01-02+88,333→ 88,333 total→ Common Stock (88,333 underlying) - Exercise/Conversion
Common Stock
2025-01-01+9,467→ 1,443,097 total - Exercise/Conversion
Common Stock
2025-01-02+29,149→ 1,468,342 total - Exercise/Conversion
Restricted Stock Units
2025-01-02−29,149→ 59,184 total→ Common Stock (29,149 underlying) - Exercise/Conversion
Restricted Stock Units
2025-01-01−9,467→ 37,867 total→ Common Stock (9,467 underlying) - Tax Payment
Common Stock
2025-01-02$2.48/sh−13,532$33,559→ 1,454,810 total
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- [F2]The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
- [F3]The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO.
- [F4]The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeother
Related Parties
1- filerCIK 0001604457
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 6:25 PM ET
- Size
- 16.8 KB